



20th December 2016

BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	19883.06	+0.20%	+14.11%
S&P 500	2262.53	+0.20%	+10.69%
Nasdaq	5457.44	+0.37%	+8.99%
Nikkei	19494.53	+0.53%	+1.88%
Stoxx 600	359.587	-0.12%	-1.70%
CAC 40	4822.77	-0.22%	+4.00%
Oil /Gold			
Crude WTI	52.12	+0.42%	+40.11%
Gold (once)	1139.66	+0.72%	+7.27%
Currencies/Rates			
EUR/USD	1.0437	+0.26%	-3.92%
EUR/CHF	1.0686	-0.25%	-1.73%
German 10 years	0.157	-27.35%	-75.20%
French 10 years	0.725	-8.62%	-26.10%
Euribor	-	+-%	+-%

Economic releases :

Date	
20th-Dec	08H00 DE - PPI 12h00 GB - CBI Industrials trends survey

Recent reports :

Date	
13th-Dec	Construction - Paris Reverse Roadshow feedback
7th-Dec	Brewers : Our takeaways from the Consumer Conference
5th-Dec	TAVI is VITAL
2nd-Dec	FD-SOI: forbidden fruit of the industry and market
29th-Nov	Morphosys We want MORE! (Fair Value EUR65 BUY)
28th-Nov	Fashion E-Commerce: Serving Consumers not Uberising Them! Coverage initiation of ZALANDO, YOOX, H&M,

List of our Reco & Fair Value : Please click here to download



DANONE

NEUTRAL, Fair Value EUR70 vs. EUR71 (+16%)

Dairy in trouble - cut in top line guidance

The weak performance by the dairy division has forced Danone to revise its 2016 guidance. The group now anticipates full year like-for-like sales growth to be slightly below previous guidance for 3-5%. EBIT margin should be above target vs prior guidance of +50-60bps. Our Fair Value is adjusted downwards to EUR70. We maintain our Neutral recommendation. We think that Danone has lost its organic growth engines (i.e. mainly Chinese water and baby food) over the past couple of months, and the integration of the WhiteWave acquisition will prevent the company from focusing on their recovery.

EDF

NEUTRAL vs. BUY, Fair Value EUR10,4 vs. EUR14,6 (+7%)

Downgrade to neutral due to ongoing low earnings visibility

Following last week's unveiling of very disappointing 2017 EBITDA guidance (EUR13.7-14.3bn), we have completely rebuilt our power price model for France and the UK. Our 2017e/2018e estimates are significantly revised downward, so is our FV, now standing at EUR10.4 per share. We downgrade EDF to neutral due to the ongoing low visibility we have on the company's earnings, the upcoming capital increase, which should negatively weigh on the stock and the risks we see in nuclear provisions. In all, we would favour Engie over EDF due to the recently increased visibility on the stock notably following recent nuclear provisions announcement and upcoming disposals likely to act as positive catalysts.

In brief...

GENMAB, Dara filed for approval in Japan. FY16 financial guidance further increased

"Dara" filed in Japan. GEN has announced that JNJ has submitted a New Drug Application to the MHLW in Japan

LUXURY GOODS, Swiss watch exports down 5.6% in November with stability in Hong Kong!

Swiss watch exports were down 5.6% in November after falling 16% in October, implying a 10.4% decrease over 11m. Together, exports to Hong Kong and Mainland China grew 2% in November following -14% in October. This was the first month of growth since January 2015! Nevertheless, this positive news would have to be confirmed in coming months to speak about a new trend!

Food & Beverages

Danone

Price EUR60.40

Dairy in trouble - cut in top line guidance

Fair Value EUR70 vs. EUR71 (+16%)

NEUTRAL

The weak performance by the dairy division has forced Danone to revise its 2016 guidance. The group now anticipates full year like-for-like sales growth to be slightly below previous guidance for 3-5%. EBIT margin should be above target vs prior guidance of +50-60bps. Our Fair Value is adjusted downwards to EUR70. We maintain our Neutral recommendation. We think that Danone has lost its organic growth engines (i.e. mainly Chinese water and baby food) over the past couple of months, and the integration of the WhiteWave acquisition will prevent the company from focusing on their recovery.

ANALYSIS

Dairy organic sales are only set to rise 0.5% in Q4 vs the previous forecast for +3%. The weak performance of the dairy division (49% of total sales) has forced Danone to revise its 2016 guidance. The group now anticipates full year like-for-like sales growth to be slightly below prior guidance of 3-5%. The EBIT margin should be above target vs prior guidance of +50-60bps. The relaunch of Activia (an estimated 30% of the European dairy sales) in mid-September, which includes a change in marketing/packaging/recipes has been disappointing for many reasons (marketing campaign excessively global, packaging problems with differentiating flavours, consumers' false belief that prices have been increased) and the brand's Q4 sales are below expectations. In addition, Spain (5% of total sales) has deteriorated, with the yoghurts category down low single digit and private labels gaining shares. The group's CFO said that the yoghurts division is expected to grow around 2% over the year, implying +0.5% in Q4 2016. This is a significant slowdown vs the first nine months of the year when dairy sales rose 2.5% organically. This is also well below our previous forecast of +3% which factored in an improvement in dairy trends in Q4 thanks to the Activia relaunch.

Organic sales growth slightly revised downwards from +3.1% to +2.9%. Today's adjustment is minor. At the Q3 sales release on 19th October, Danone indicated it would hit the low end of the guidance. We now expect 2.9% organic sales growth vs +3.1% previously. According to the CFO, the EBIT margin increase in LFL in 2016 should be 5-10bps higher than the prior guidance range. Our current estimate now calls for +70bps vs +60bps before. All the savings that are extracted are not reinvested as there is no need to push for short-term growth in the current environment.

No change in trend in the other divisions to be expected. Ms Cabanis indicated that the trends in the other divisions remain unchanged vs what was said previously. We forecast Waters (22% of total sales) to increase 8% organically in the last quarter of the year. The destocking of the brand Mizone continues as the growth of the non-alcoholic beverages market in China is basically zero (it was high single digit ten months ago) but the comparison base is highly favourable. On an organic basis, Early Life nutrition (22% of total sales) should drop 1% as a result of the shrinking of the grey market and destocking of traders operating in this channel. The regulation of the infant milk industry in China is proving highly disruptive. The Australian baby food company Bellamy's has been granted a trading halt in order to finalise an updated announcement of the impact of trading conditions on its financial results. The Chinese company Mengniu has said it expects to record substantial loss, citing impairment provision after unit Yashili's losses.

WhiteWave to be integrated in Q1 2017. Last Friday, the group was granted clearance of the European activities for the WhiteWave acquisition. The transaction is still under review by the DOJ. Yesterday Danone has confirmed that the closing and integration of the US company should occur in Q1 2017 (vs Q4 2016 when the transaction was announced).

VALUATION / NEXT CATALYST

Our Fair Value is adjusted downwards to EUR70. We maintain our Neutral recommendation. We think Danone has lost its organic growth engines (ie mainly Chinese water and baby food) over the past couple of months and the integration of the WhiteWave acquisition will prevent the company from focusing on their recovery. We see 2018 as the turning point as organic sales growth will be supported by the WhiteWave acquisition and the infant milk industry in China will start to normalise. The group will release its 2016 results on 15th February.

[Click here to download](#)

Bloomberg	BN FP
Reuters	DANO.PA
12-month High / Low (EUR)	70.3 / 58.0
Market Cap (EUR)	39,616
Ev (BG Estimates) (EUR)	57,903
Avg. 6m daily volume (000)	1 735
3y EPS CAGR	8.8%

	1 M	3 M	6 M	31/12/15
Absolute perf.	2.7%	-6.6%	0.8%	-3.0%
Food & Bev.	4.2%	-4.8%	0.2%	-5.7%
DJ Stoxx 600	6.0%	5.4%	10.4%	-1.7%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	22,412	21,886	26,044	27,347
% change		-2.3%	19.0%	5.0%
EBIT	2,892	3,018	3,545	3,823
% change		4.4%	17.5%	7.8%
Net income	1,791	1,897	2,116	2,326
% change		5.9%	11.6%	9.9%

	2015	2016e	2017e	2018e
Operating margin	12.9	13.8	13.6	14.0
Net margin	8.0	8.7	8.1	8.5
ROE	10.2	14.9	16.4	16.6
ROCE	11.0	12.6	14.3	15.2
Gearing	61.6	140.8	125.7	110.8

(EUR)	2015	2016e	2017e	2018e
EPS	2.93	3.08	3.44	3.77
% change	-	5.1%	11.6%	9.9%
P/E	20.6x	19.6x	17.6x	16.0x
FCF yield (%)	4.1%	4.6%	5.0%	5.4%
Dividends (EUR)	1.60	1.68	1.88	2.06
Div yield (%)	2.6%	2.8%	3.1%	3.4%
EV/Sales	2.1x	2.6x	2.2x	2.1x
EV/EBIT	16.4x	19.2x	16.1x	14.7x



Analyst :
 Virginie Roumage
 33(0) 1.56.68.75.22
 vroumage@bryangarnier.com

Sector Team :
 Nikolaas Faes
 Loic Morvan
 Antoine Parison
 Cédric Rossi

Utilities

EDF

Price EUR9.76

Downgrade to neutral due to ongoing low earnings visibility

Fair Value EUR10,4 vs. EUR14,6 (+7%)

NEUTRAL vs. BUY

Bloomberg	EDF.FP
Reuters	EDF.PA
12-month High / Low (EUR)	13.7 / 9.2
Market Cap (EUR)	20,585
Ev (BG Estimates) (EUR)	82,708
Avg. 6m daily volume (000)	1,948
3y EPS CAGR	-25.8%

	1 M	3 M	6 M	31/12/15
Absolute perf.	-0.4%	-10.7%	-12.7%	-28.1%
Utilities	6.9%	-4.4%	-4.0%	-10.2%
DJ Stoxx 600	6.0%	5.4%	10.4%	-1.7%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	75,006	74,664	72,961	73,843
% change		-0.5%	-2.3%	1.2%
EBITDA	17,601	16,009	14,062	15,632
EBIT	4,280	6,979	4,581	5,677
% change		63.1%	-34.4%	23.9%
Net income	4,231	2,924	1,230	1,864
% change		-30.9%	-57.9%	51.5%

	2015	2016e	2017e	2018e
Operating margin	5.7	9.3	6.3	7.7
Net margin	5.6	3.9	1.7	2.5
ROE	10.5	5.6	1.5	3.1
ROCE	2.0	2.8	2.0	2.4
Gearing	167.6	165.5	162.8	164.0


(EUR)	2015	2016e	2017e	2018e
EPS	2.27	1.46	0.61	0.93
% change		-36.0%	-57.9%	51.6%
P/E	4.3x	6.7x	15.9x	10.5x
FCF yield (%)	NM	NM	NM	8.8%
Dividends (EUR)	1.10	0.87	0.37	0.56
Div yield (%)	11.3%	9.0%	3.8%	5.7%
EV/Sales	1.1x	1.1x	1.1x	1.1x
EV/EBITDA	4.6x	5.2x	5.9x	5.4x
EV/EBIT	18.7x	11.9x	18.1x	14.8x

Following last week's unveiling of very disappointing 2017 EBITDA guidance (EUR13.7-14.3bn), we have completely rebuilt our power price model for France and the UK. Our 2017e/2018e estimates are significantly revised downward, so is our FV, now standing at EUR10.4 per share. We downgrade EDF to neutral due to the ongoing low visibility we have on the company's earnings, the upcoming capital increase, which should negatively weigh on the stock and the risks we see in nuclear provisions. In all, we would favour Engie over EDF due to the recently increased visibility on the stock notably following recent nuclear provisions announcement and upcoming disposals likely to act as positive catalysts.

ANALYSIS

- Last week, EDF unveiled its 2017e EBITDA guidance (between EUR13.7bn and EUR14.3bn), which was 9% to 13% below consensus expectations and which implies a 11% to 16% yoy decrease vs. the 2016e unchanged company EBITDA guidance (EUR16.0-16.3bn). The main reasons for this decrease were the expected decrease in French and UK power prices as well as higher ARENH volumes subscriptions for 2017. Since this announcement, the stock has clearly been under pressure (-12.9% vs. +1.2% for the Stoxx 600 Utilities).
- We have completely rebuilt our power price model and slashed our estimates for both the French and UK business divisions. EDF does not disclose its hedging policy, but we estimate a standard 3-year rolling policy would imply a c. EUR4.5/MWh decrease in the company's achieved French and UK power prices in 2017 vs. 2016. We additionally assume that ARENH volume subscriptions will have a c. EUR300m negative impact on the company's 2017e EBITDA, based on a 50TWh subscribed volumes' assumption for 2017. In all, we now expect 2016e/2017e/2018e EBITDA to reach EUR16.0bn/EUR14.1bn/EUR15.6bn respectively. After a significant drop in 2017, we expect a substantial rebound in 2018 notably given the current level of forward prices.

Table 1: BG assumptions for French power prices (2016e-2018e) – EUR/MWh



- We have also integrated the expected disposal of a 49.9% stake in grid operator RTE which should bring up to EUR4.2bn cash-in for EDF in 2017. This is the only expected disposal we have integrated in our model. All in all, our FV – based on an equally weighted valuation of three methods (SOTP, P/E ratio, Div. yield) – now stands at EUR10.4 per share, implying therefore a limited 7% theoretical upside vs. current company's share price.

Table 2: BG key estimates (2016e-2018e)

	2016e	2017e	2018e
EBITDA	16,009	14,062	15,632
<i>o/w France</i>	<i>11,063</i>	<i>9,027</i>	<i>10,383</i>
<i>o/w UK</i>	<i>1,665</i>	<i>1,568</i>	<i>1,583</i>
EBIT	6,979	4,581	5,677
Net income	2,924	1,230	1,864
EPS	1.46	0.61	0.93
DPS	0.87	0.37	0.56

Source : Bryan Garnier & Co. ests.

- Downgrade to neutral:** despite the recent strong derating (-12.9% performance since the profit warning), we downgrade EDF to Neutral due to the high earnings volatility and the ongoing low visibility we have on the company's earnings (nuclear outages, hedge policy not disclosed by the company), as shown by the three profit warnings over the last five months. In addition, momentum appears rather poor in our view with the upcoming EUR4bn capital increase (scheduled for March 2017) likely to negatively weigh on the stock on top of the uncertainty



related to 2017 French presidential elections. Finally, we see risks that nuclear provisions may be increased as EDF's used discount rate (4.4%) still appears uncorrelated to the market environment. The company's reference document unveiled that a 20bps decrease in the discount rate would imply a c. EUR1.2bn increase in provisions as well as a c. EUR600m headwind at the pre-tax income level. As a reminder, last week, the discount rate used by Engie for its Belgian nuclear provisions has been revised downward by 130bps from 4.8% to 3.5%.

Table 3: Nuclear provisions – sensitivity to discount rate

Nuclear provisions France - sensitivity to discount rate					
	Amount in the balance sheet	Balance sheet provisions		Pre-tax income	
		+ 0,20%	-0,20%	+ 0,20%	-0,20%
Back-end nuclear cycle expenses					
○ Spent fuel management	10,391	(168)	177	140	(149)
○ Long-term radioactive waste management	8,254	(400)	448	337	(376)
Decommissioning and last cores					
○ Decommissioning of nuclear power plants	14,930	(496)	522	122	(131)
○ Last cores	2,555	-62	65	-	-
Total	36,130	(1,126)	1,212	599	(656)

Source : Company – 2015 Reference Document

- As for the dividend, our 2017e EPS estimate and our unchanged 60% payout ratio imply a mere 3.7% yield, well below sector standards. As a reminder, EDF's dividend policy implies a 55-65% payout ratio for 2016 and an option for scrip dividends for both FY16 and FY17. This would imply further dilution at the EPS level.
- In all, we would favour Engie (Buy, FV @ EUR14.8) over EDF (Neutral, FV @ EUR10.4). We believe Engie's visibility has clearly been improved over the past few weeks following the company's recent announcement over Belgian nuclear provisions. The "no-growth" scenario for 2016-2018 has been priced-in by the market and the consensus has already started to revise downward its initial estimates. We now expect Engie to keep delivering its transformation plan with the awaited E&P assets' disposal still remaining the main short-term positive catalyst on the stock.

VALUATION

- At the current share price, the stock trades at 5.2x its 2016e EV/EBITDA multiple.
- Neutral, FV @ EUR10.4 per share

NEXT CATALYSTS

- 14th February 2017: FY-16 results

[Click here to download](#)



Analyst :
 Pierre-Antoine Chazal
 33(0) 1.56.68.75.06
 pchazal@bryangarnier.com

Sector Team :
 Xavier Caroen

Healthcare

Genmab

Price DKK1,150

Dara filed for approval in Japan. FY16 financial guidance further increased**Fair Value DKK1900 (+65%)****BUY**

Bloomberg	GEN DC
Reuters	GEN.CO
12-month High / Low (DKK)	1,266 / 638.0
Market Cap (DKKm)	69,403
Avg. 6m daily volume (000)	328.3

	1 M	3 M	6 M	31/12/15
Absolute perf.	-7.7%	4.7%	4.8%	25.3%
Healthcare	2.8%	-4.1%	1.3%	-11.0%
DJ Stoxx 600	6.0%	5.4%	10.4%	-1.7%

	2015	2016e	2017e	2018e
P/E	NS	80.3x	63.5x	32.4x
Div yield (%)	NM	NM	NM	NM

ANALYSIS

- **"Dara" filed in Japan.** GEN has announced that JNJ has submitted a New Drug Application to the MHLW in Japan (where we see an annual incidence of 5-10,000) for the use of daratumumab for treatment of adults with multiple myeloma (knowing that the package includes its three pivotal studies, i.e. SIRIUS, CASTOR and POLLUX).
- **Updated financial guidance.** The event triggered the payment of a USD10m milestone to GEN, which obviously was not expected this year prompting management to further increase its financial guidance to include it. Consequently, the company now expects its revenues to be in the range of DKK1,720-1,770m (+DKK70m compared to the previous figure).

	BG	New guidance	Former guidance
GEN Revenues (DKKm)	1,783	1,720-1,770	1,650-1,700
"Dara" royalties (DKKm)	466	400-450	400-450
Operating expenses (DKKm)	836	800-850	800-850
Operating income (DKKm)	947	895-945	825-8753
Cash position at year end (DKKm)	3,807	3,650-3,750	3,650-3,750

Note: there is no change to the cash position as the additional milestone payment is expected to be received shortly after year-end

VALUATION

- **BUY reiterated with a FV of DKK1,900.**

NEXT CATALYSTS

- 24th January 2017: JNJ's Q4 2016 results. 22nd February 2016: GEN's Q4 2016 results.

[Click here to download](#)

Mickael Chane Du, mchanedu@bryangarnier.com

Sector View

Luxury Goods

Swiss watch exports down 5.6% in November with stability in Hong Kong!

	1 M	3 M	6 M	31/12/15
Pers & H/H Gds	5.2%	0.5%	4.3%	0.4%
DJ Stoxx 600	6.4%	6.6%	12.1%	-1.6%

*Stoxx Sector Indices

Companies covered

BURBERRY	NEUTRAL	1350p
CHRISTIAN DIOR	BUY	EUR190
HERMES Intl	BUY	EUR410
HUGO BOSS	NEUTRAL	EUR70
KERING	BUY	EUR218
LVMH	BUY	EUR194
MONCLER	BUY	EUR17,5
PRADA	NEUTRAL	HKD31
RICHEMONT	BUY	CHF73
SALVATORE	NEUTRAL	EUR23,8
THE SWATCH GROUP	NEUTRAL	CHF320
TOD'S GROUP	SELL	EUR53

Swiss watch exports were down 5.6% in November after falling 16% in October, implying a 10.4% decrease over 11m. Together, exports to Hong Kong and Mainland China grew 2% in November following -14% in October. This was the first month of growth since January 2015! Nevertheless, this positive news would have to be confirmed in coming months to speak about a new trend!

ANALYSIS

With a 5.6% decrease, Swiss watch exports remained under pressure in November, albeit to a lesser extent than in October (-16%). We would highlight that during the month, exports were still stable in Hong Kong (12% of total exports), following -20% in October, in the first clear sign of sequential improvement for almost two years (January 2015)! It nevertheless implies -25% for 11 months, while momentum was slightly positive in Mainland China (6% of total exports) with 6% growth. Over 11m, exports to Mainland China, were down no more than 6%. The situation is clearly improving in Greater China (together exports to HK and MC were up 2% in November)!

Among others countries, note the 18% decline in the US, following -16% in October, the second biggest country for the industry with 11% of total exports, and the still-positive trend in the UK (+6.5%), even if others European countries were less well oriented, particularly France and Italy which delivered poor figures again (respectively -19% and -12%).

By price segment, high-end watches (above CHF3,500 export price) incurred a 7% decline in exports in November while in the mid-range segment (CHF200-CHF500, export price), exports were down 8.5%. Positive news in November stemmed from the range between CHF500 and CHF3,000 where exports rose 2.6%.

NEXT CATALYSTS

FY 2016 Swiss watches exports to be released on

Loïc Morvan, lmorvan@bryangarnier.com

BG's Wake Up Call

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 54.9%

NEUTRAL ratings 35.2%

SELL ratings 9.9%

Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/Infrastructures/Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Automotive & Parts		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager		Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Munich
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA)	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle Prudential et de Résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11



BRYAN, GARNIER & Co

Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....